A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Titel:
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Auteur:
Bellone, S. Roque, D.M. Siegel, E.R. Buza, N. Hui, P. Bonazzoli, E. Guglielmi, A. Zammataro, L. Nagarkatti, N. Zaidi, S. Lee, J. Silasi, D.-A. Huang, G.S. Andikyan, V. Damast, S. Clark, M. Azodi, M. Schwartz, P.E. Tymon-Rosario, J. Harold, J. Mauricio, D. Zeybek, B. Menderes, G. Altwerger, G. Ratner, E. Alexandrov, L.B. Iwasaki, A. Kong, Y. Song, E. Dong, W. Elvin, J. Choi, J. Santin, A.D.